Chronic Hepatitis B (HBV)

Hepatitis B virus infection becomes chronic when the immune system cannot clear the virus within six months. Chronic HBV can remain inactive for decades or progress to cirrhosis and hepatocellular carcinoma. Regular monitoring and timely antiviral therapy are critical to protect liver health.

Transmission & Risk Factors

• Birth from an HBV-positive parent (perinatal transmission)
• Unprotected sex, sharing needles, or contaminated medical equipment
• Household contact with infected blood or open sores
• Dialysis, immunosuppression, chemotherapy
• Regions with high HBV endemicity (Asia-Pacific, Africa)

Natural History Phases

1. Immune Tolerant: High HBV DNA, normal ALT, minimal inflammation (common in perinatally infected children).

2. Immune Active (HBeAg-positive): Elevated ALT, high HBV DNA, active inflammation.

3. Inactive Carrier (HBeAg-negative): Low HBV DNA, normal ALT.

4. HBeAg-negative Chronic Hepatitis: Fluctuating viremia and ALT elevation.

Diagnosis & Staging

• Serologies: HBsAg, HBeAg, anti-HBe, anti-HBs
• Quantitative HBV DNA viral load
• ALT/AST, bilirubin, albumin, INR
• Non-invasive fibrosis assessment: FibroScan, APRI, FIB-4
• Ultrasound + AFP every 6 months for hepatocellular carcinoma (HCC) screening in at-risk groups
• Liver biopsy if staging unclear

Treatment Indications

Consider antiviral therapy if:

• HBV DNA ≥ 2,000 IU/mL and ALT > ULN with fibrosis/inflammation
• Cirrhosis regardless of HBV DNA
• HBV DNA > 200,000 IU/mL in pregnant patients (to reduce transmission)
• Immunosuppressed or co-infected (HCV, HDV, HIV)

Antiviral Options

• High-barrier nucleos(t)ide analogues: Tenofovir (TDF/TAF) and entecavir.
• Pegylated interferon: Finite course with higher rates of HBsAg loss in select patients.
• Lifelong therapy often required unless functional cure achieved (HBsAg loss).

Monitoring

• ALT, HBV DNA every 3–6 months depending on phase
• Kidney function and bone density for tenofovir
• Adherence to HCC surveillance even on therapy
• Vaccinate household contacts with HBV vaccine

Lifestyle & Support

• Avoid alcohol, limit hepatotoxic meds/supplements
• Maintain healthy weight (NAFLD worsens HBV)
• Safe sex practices, do not share razors/toothbrushes
• Emotional support—stigma and anxiety are common

Complications

• Cirrhosis with portal hypertension
• Hepatocellular carcinoma (even with normal ALT)
• Hepatic decompensation or acute-on-chronic liver failure
• Co-infections (HDV) accelerate progression

Research & Future Directions

Functional cure (HBsAg loss) is the holy grail. Research focuses on immune modulators, entry inhibitors, siRNA, and combination regimens to awaken immune control.

Experimental & Emerging Treatments

• siRNA & Antisense Oligonucleotides: Agents like JNJ-3989 silence HBV transcripts, lowering HBsAg levels.
• Capsid Assembly Modulators: Disrupt HBV replication by targeting core protein.
• Therapeutic Vaccines & TLR Agonists: Aim to reboot HBV-specific immunity.
• Entry Inhibitors (bulevirtide-like): Block HBV entry into hepatocytes; currently approved for HDV, studied for HBV.

Track HBV with Diagnoza.care

Stay Ahead of Hepatitis B – Log labs (ALT, HBV DNA), medications, imaging, vaccinations, and symptoms, schedule hepatology visits and ultrasounds, capture side effects, and let the AI companion highlight trends that warrant earlier intervention.

---

Medical Disclaimer: Informational only. Follow your hepatologist’s guidance for antiviral therapy, monitoring intervals, and family screening. Sources: American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), World Health Organization